Securities Registration (section 12(b)) (8-a12b)
April 24 2018 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-A
FOR
REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Eloxx
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
84-1368850
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
950 Winter Street
Waltham, Massachusetts
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
to be so registered
|
|
Name of each exchange on which
each class is to be registered
|
Common Stock, $0.01 par value per share
|
|
The Nasdaq Stock Market, LLC
|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to
Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this
form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates:
333-224207
Securities to be registered pursuant to Section 12(g) of the Act:
None
.
Item 1. Description of Registrants Securities to be Registered.
The description of the common stock, par value $0.01 per share (the Common Stock), of Eloxx Pharmaceuticals, Inc. (the Company), to be
registered hereunder is contained in the section entitled Description of Capital Stock in the prospectus forming a part of the Companys Registration Statement on Form
S-3
(Registration
No. 333-224207),
initially filed with the Securities and Exchange Commission (the Commission) on April 10, 2018, as subsequently amended from time to time (the Registration
Statement), and is incorporated herein by reference. The prospectus to be filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which will constitute part of the Registration Statement, shall be deemed
to be incorporated herein by reference.
Item 2. Exhibits.
Pursuant to the instructions as to exhibits with respect to Form
8-A,
no exhibits are required to be filed because no
other securities of the Company are registered on The Nasdaq Stock Market, LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this
registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
|
|
|
|
|
Date: April 24, 2018
|
|
|
|
Eloxx Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Gregory Weaver
|
|
|
|
|
|
|
|
|
Gregory Weaver
Chief Financial
Officer
|
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024